First Study to Demonstrate that PD1 Immune Checkpoint Blockade May Yield Clinical-Pathologic Regression in Some Patients with High-Risk Oral Precancerous Disease
Findings from a phase II non-randomised controlled study in patients with high-risk oral proliferative verrucous leukoplakia